Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.

Rachel M Williams, Anna McDonald, Martin O'Savage, David B Dunger

University of Cambridge, Department of Paediatrics, Addenbrookes Hospital, Box 116, Hills Road, Cambridge CB2 2QQ, UK.

Expert opinion on drug metabolism & toxicology 2008 Mar

filter terms:

Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to rhIGFBP-3, was developed in an attempt to prolong the half-life of IGF-I and potentially reduce side effects. It is administered as a once-daily subcutaneous injection. Treatment with rhIGF-I has been explored in a number of growth and endocrine disorders. To review the published literature regarding the pharmacokinetics, safety profile and clinical efficacy of Mecasermin rinfabate. A comprehensive search via the NCBI PubMed portal was performed using the search terms rhIGF-I/rhIGFBP-3 complex, iPLEX and Somatokine. The effects of Mecasermin rinfabate have been explored in a number of clinical situations including diabetes, severe insulin resistance, osteopaenia, burns and growth hormone insensitivity syndrome, with outcomes similar to those of rhIGF-I alone. The biological effects of Mecasermin rinfabate are largely similar to those previously reported with rhIGF-I. There are little published data pertaining to pharmacokinetic properties in human subjects, and the side effect profile appears similar to that of rhIGF-I alone.

Citation

Rachel M Williams, Anna McDonald, Martin O'Savage, David B Dunger. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. Expert opinion on drug metabolism & toxicology. 2008 Mar;4(3):311-24